PE20151138A1 - Pirazoloes sustituidos como bloqueadores del canal de calcio tipo n - Google Patents

Pirazoloes sustituidos como bloqueadores del canal de calcio tipo n

Info

Publication number
PE20151138A1
PE20151138A1 PE2015000206A PE2015000206A PE20151138A1 PE 20151138 A1 PE20151138 A1 PE 20151138A1 PE 2015000206 A PE2015000206 A PE 2015000206A PE 2015000206 A PE2015000206 A PE 2015000206A PE 20151138 A1 PE20151138 A1 PE 20151138A1
Authority
PE
Peru
Prior art keywords
alkyl
calcium channel
channel blockers
type calcium
pyrazoles substituted
Prior art date
Application number
PE2015000206A
Other languages
English (en)
Spanish (es)
Inventor
Mark Wall
Nalin Subasinghe
Zhihua Sui
Christopher Flores
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49034268&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20151138(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of PE20151138A1 publication Critical patent/PE20151138A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PE2015000206A 2012-08-16 2013-08-16 Pirazoloes sustituidos como bloqueadores del canal de calcio tipo n PE20151138A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261683774P 2012-08-16 2012-08-16

Publications (1)

Publication Number Publication Date
PE20151138A1 true PE20151138A1 (es) 2015-08-07

Family

ID=49034268

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2015000206A PE20151138A1 (es) 2012-08-16 2013-08-16 Pirazoloes sustituidos como bloqueadores del canal de calcio tipo n

Country Status (18)

Country Link
US (1) US9434693B2 (fr)
EP (1) EP2885278B1 (fr)
JP (1) JP6262732B2 (fr)
KR (1) KR20150042269A (fr)
CN (1) CN104884438B (fr)
AU (1) AU2013302468B2 (fr)
BR (1) BR112015003393A2 (fr)
CA (1) CA2882038A1 (fr)
CL (1) CL2015000360A1 (fr)
CR (1) CR20150067A (fr)
EA (1) EA201590381A1 (fr)
IL (1) IL237190A0 (fr)
IN (1) IN2015DN01238A (fr)
MX (1) MX2015002036A (fr)
PE (1) PE20151138A1 (fr)
PH (1) PH12015500316A1 (fr)
SG (1) SG11201501130PA (fr)
WO (1) WO2014028800A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9974775B2 (en) 2013-08-16 2018-05-22 Janssen Pharmaceutica Nv Substituted imidazoles as N-type calcium channel blockers

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6450314B2 (ja) 2012-08-21 2019-01-09 ヤンセン ファーマシューティカ エヌ．ベー． クエチアピンハプテンに対する抗体及びその使用
JP6389176B2 (ja) 2012-08-21 2018-09-12 ヤンセン ファーマシューティカ エヌ．ベー． アリピプラゾールハプテンに対する抗体及びその使用
JP6131414B2 (ja) 2012-08-21 2017-05-24 ヤンセン ファーマシューティカ エヌ．ベー． アリピプラゾールのハプテン及びイムノアッセイにおけるそれらの使用
PL2888592T3 (pl) 2012-08-21 2018-03-30 Janssen Pharmaceutica Nv Przeciwciała względem kwetiapiny i ich zastosowania
CA2882596C (fr) 2012-08-21 2019-05-14 Ortho-Clinical Diagnostics, Inc. Anticorps diriges contre l'olanzapine et leur utilisation
WO2014031656A1 (fr) 2012-08-21 2014-02-27 Ortho-Clinical Diagnostics, Inc Anticorps dirigés contre des haptènes d'olanzapine et leur utilisation
CA2882562C (fr) 2012-08-21 2019-08-27 Eric Hryhorenko Anticorps diriges contre l'aripiprazole et leur utilisation
ES2691092T3 (es) 2012-08-21 2018-11-23 Janssen Pharmaceutica Nv Anticuerpos contra la risperidona y uso de los mismos
JP2015529199A (ja) 2012-08-21 2015-10-05 オルソ−クリニカル ダイアグノスティクス，インコーポレイティド パリペリドンハプテンに対する抗体及びその使用
JP2015527365A (ja) 2012-08-21 2015-09-17 オルソ−クリニカル ダイアグノスティクス，インコーポレイティド パリペリドンに対する抗体及びその使用
EP2888284B1 (fr) 2012-08-21 2022-07-06 Janssen Pharmaceutica NV Anticorps dirigés contre des haptènes de rispéridone et leur utilisation
TW201718557A (zh) * 2015-10-08 2017-06-01 歌林達有限公司 經吡唑基取代之四氫吡喃基碸
TW201726128A (zh) * 2015-10-08 2017-08-01 歌林達有限公司 經吡唑基取代之四氫哌喃基碸
EP3390449A1 (fr) 2015-12-17 2018-10-24 Janssen Pharmaceutica N.V. Anticorps anti-rispéridone et leur utilisation
US10435478B2 (en) 2015-12-17 2019-10-08 Janssen Pharmaceutica Nv Antibodies to quetiapine and use thereof
EP3478665A1 (fr) * 2016-06-29 2019-05-08 Esteve Pharmaceuticals, S.A. Dérivés de pyrazole ayant une activité contre la douleur

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643933A (en) 1995-06-02 1997-07-01 G. D. Searle & Co. Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors
IT1287174B1 (it) 1996-11-15 1998-08-04 Angelini Ricerche Spa Diaril-ciclometilenpirazoli farmacologicamente attivi,procedimento per prepararli e composizioni farmaceutiche che li contengono
US20010036943A1 (en) * 2000-04-07 2001-11-01 Coe Jotham W. Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines
WO2004060367A1 (fr) * 2002-12-30 2004-07-22 Fujisawa Pharmaceutical Co., Ltd. Derives d'imidazole et de triazole utiles en tant qu'inhibiteurs de cox-1 selectifs
US7145012B2 (en) 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
NZ546834A (en) 2003-10-01 2010-03-26 Adolor Corp Spirocyclic heterocyclic derivatives and methods of their use
FR2864958B1 (fr) 2004-01-12 2006-02-24 Sanofi Synthelabo Derive de n-[(1,5-diphenyl-1h-pyrazol-3-yl)methyl] sulfonamide, leur preparation et leur application en therapeutique.
US7598261B2 (en) 2005-03-31 2009-10-06 Adolor Corporation Spirocyclic heterocyclic derivatives and methods of their use
TWI411607B (zh) 2005-11-14 2013-10-11 Vitae Pharmaceuticals Inc 天門冬胺酸蛋白酶抑制劑
WO2009000085A1 (fr) * 2007-06-27 2008-12-31 Painceptor Pharma Corporation Dérivés de quinoline et de quinazoline utiles comme modulateurs des canaux ioniques
JO3240B1 (ar) 2007-10-17 2018-03-08 Janssen Pharmaceutica Nv c-fms مثبطات كيناز
ES2439767T3 (es) 2008-08-01 2014-01-24 Purdue Pharma Lp Compuestos de tetrahidropiridinilo y dihidropirrolilo y uso de los mismos
WO2010021680A2 (fr) 2008-08-19 2010-02-25 Vitae Pharmaceuticals, Inc. Inhibiteurs de la bêta-sécrétase
KR101052065B1 (ko) * 2008-10-15 2011-07-27 한국과학기술연구원 칼슘이온 채널 조절제로서 유효한 피라졸릴메틸아민-피페라진 유도체와 이의 제조방법
CN104903316B (zh) 2012-08-16 2017-11-28 詹森药业有限公司 作为n型钙通道阻滞剂的取代的吡唑
KR20150042271A (ko) 2012-08-16 2015-04-20 얀센 파마슈티카 엔.브이. N형 칼슘 채널 차단제로서의 치환된 피롤로피라졸
HK1217690A1 (zh) 2012-08-16 2017-01-20 Janssen Pharmaceutica Nv 作爲n型钙通道阻滞剂的环戊基吡唑

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9974775B2 (en) 2013-08-16 2018-05-22 Janssen Pharmaceutica Nv Substituted imidazoles as N-type calcium channel blockers

Also Published As

Publication number Publication date
EA201590381A1 (ru) 2015-07-30
US9434693B2 (en) 2016-09-06
SG11201501130PA (en) 2015-04-29
CA2882038A1 (fr) 2014-02-20
KR20150042269A (ko) 2015-04-20
CL2015000360A1 (es) 2015-04-24
JP2015524850A (ja) 2015-08-27
WO2014028800A1 (fr) 2014-02-20
CN104884438B (zh) 2017-07-28
IL237190A0 (en) 2015-04-30
BR112015003393A2 (pt) 2017-07-04
CR20150067A (es) 2015-04-30
CN104884438A (zh) 2015-09-02
AU2013302468B2 (en) 2017-08-24
EP2885278A1 (fr) 2015-06-24
EP2885278B1 (fr) 2016-08-03
PH12015500316A1 (en) 2015-03-30
US20140162997A1 (en) 2014-06-12
JP6262732B2 (ja) 2018-01-17
AU2013302468A1 (en) 2015-02-26
IN2015DN01238A (fr) 2015-06-26
MX2015002036A (es) 2016-01-22

Similar Documents

Publication Publication Date Title
PE20151138A1 (es) Pirazoloes sustituidos como bloqueadores del canal de calcio tipo n
NI201000013A (es) Sulfonamidas como moduladores del trpm8
CR9048A (es) Analogos de anilino-pirimidina
HN2011000341A (es) Compuestos derivados de sulfonamidas, composiciones farmaceuticos y proceso de preparacion de los mismos
PE20180030A1 (es) Compuestos biciclicos de sulfonamida cetona
PE20151139A1 (es) Pirrolopirazoles como bloqueadores del canal de calcio tipo n
PE20161065A1 (es) Inhibidores de bromodominio
PE20142456A1 (es) COMPUESTOS DE OXAZOLIDIN-2-ONA Y USOS DE LOS MISMOS COMO INHIBIDORES DE LA PI3Ks
PE20191204A1 (es) Modificador del sabor dulce
MX379304B (es) Compuestos antihelminticos, composiciones y metodo para usar los mismos.
EA201500557A1 (ru) Антигельминтные соединения, композиции и способы их применения
EA201590868A1 (ru) Противовирусные соединения
PH12015502192A1 (en) Novel compounds
EA201790963A1 (ru) Противовирусные соединения
MX2012012902A (es) Analogos heteroarilo biciclicos como moduladores de receptor acoplado a la proteina g gpr119.
PE20151140A1 (es) Pirazoles sustituidos como bloqueadores del canal de calcio tipo n
PE20151429A1 (es) Dihidropirimidinonas biciclicas sustituidas y su uso como inhibidores de la actividad de elastasa neutrofilica
PE20151006A1 (es) Derivados de oxazolidin-2-ona-pirimidina
PE20150774A1 (es) Aminoquinolinas como inhibidores de cinasa
AR087515A1 (es) Compuestos de n-tio-antranilamida y sus usos como plaguicidas
PE20150021A1 (es) 5-amino[1,4]tiazinas como inhibidores de bace1
PE20151158A1 (es) Moduladores selectivos del receptor de androgenos novedosos
PE20151137A1 (es) Ciclopentilpirazoles como bloqueadores del canal de calcio tipo n
MX345104B (es) Composición herbicida.
PE20142433A1 (es) Proceso para la elaboracion de undecapeptidos ciclicos

Legal Events

Date Code Title Description
FD Application declared void or lapsed